Takako Shimamoto

Characterization of Human Placental Activity for Transport of L-alanine, Using Brush Border (Microvillous) Membrane Vesicles

The uptake of taurocholate into brush border membrane vesicles prepared from human full term placenta was studied using a rapid filtration technique. The taurocholate uptake into brush border membrane vesicles was sensitive to extravesicular osmolarity, and pre-incubation of the brush border membrane vesicles with the taurocholate increased the uptake of taurocholate into the brush border membrane vesicles. These findings indicate that the uptake of taurocholate by brush border membrane vesicles represents transport into vesicles. The uptake of taurocholate into vesicles was not dependent on Na+ electrochemical gradient (extravesicular > intravesicular). But this uptake was markedly increased when the intravesicular space was rendered electrically more positive by the use of lowly permeant anions or valinomycin-induced K+ diffusion membrane potentials. These findings indicate that the taurocholate transport into brush border membrane vesicles was dependent on membrane potential. The initial rate of taurocholate transport into brush border membrane vesicles exhibited saturation kinetics with respect to the taurocholate concentration, an apparent Km of 67 microM and Vmax of 0.30 nmol/mg protein/20 sec were calculated.

Platelet aggregation inhibiting activity of human placental chorioepithelial brush border membrane vesicles.

We investigated the platelet aggregation inhibiting activity of human placental brush border membrane vesicles (BBMV) and obtained the following results. A strong platelet aggregation inhibiting activity existed in placental BBMV. The BBMV inhibited the platelet aggregation induced by ADP, arachidonic acid, collagen and ristocetin in a dose-dependent manner. The protein concentration of BBMV giving 50 per cent inhibition was 52 +/- 6 micrograms/ml for ADP-induced platelet aggregation, 21 +/- 2 micrograms/ml for arachidonic acid-induced platelet aggregation, 19 +/- 2 micrograms/ml for collagen-induced platelet aggregation and 107 +/- 9 micrograms/ml for ristocetin-induced platelet aggregation. There was a high level of ADP degrading activity (ADPase activity) in the placental BBMV. ADP degrading activity of the BBMV: 10.5 +/- 0.5 mumol/mg protein/min was 21 times greater than that of homogenate of the placental villi. The placental BBMV inhibited platelet TXA2 production. In the 40 micrograms/ml protein concentration of placental BBMV, platelet TXA2 production was almost completely inhibited.

Platelet aggregation inhibiting activity of human placental chorioepithelial brush border membrane vesicles: the role of alkaline phosphatase

Human placental chorioepithelial brush border membrane, which is in direct contact with maternal blood flow, has platelet aggregation inhibiting activity. In the present study, the mechanism of this action has been examined in relation to ADP (adenosine diphosphate) degrading activity and alkaline phosphatase activity of brush border membrane vesicles (BBMV). BBMV prepared from human early and term placental villi, inhibited platelet aggregation induced by ADP. BBMV had potent ADP degrading (ADPase) activity. ADP was quickly degraded by BBMV. ADP degrading activity of BBMV was not so different between early and term placenta. Alkaline phosphatase activity of late placental BBMV was about three times greater than that of early placental BBMV. On the other hand, ADP degrading activity of late placental BBMV was almost the same as that of early placental BBMV. Inhibiting activity of platelet aggregation induced by ADP and ADP degrading activity of BBMV, were not inhibited by levamisole (alkaline phosphatase inhibitor).

Studies on placental inhibition of platelet aggregation: A comparison of human syncytiotrophoblast brush border and basal plasma membranes

We compared the platelet aggregation inhibiting activity of human placental syncytiotrophoblast brush border membrane vesicles (BBMV) and basal plasma membrane vesicles (BpMV), and obtained the following results. Strong platelet aggregation inhibiting activity is found in placental BBMV. BBMV inhibited platelet aggregation induced by ADP (adenosine diphosphate) and arachidonic acid in a way which depended on the protein concentration of BBMV added. In contrast, BpMV showed no detectable platelet aggregation inhibiting activity. Quite high ADP degrading activity (ADPase activity) was present in the placental BBMV. ADP was quickly degraded by BBMV. In contrast, BpMV did not degrade ADP so quickly. Platelet TXB2 production was almost completely abolished at the protein concentration of 40 micrograms/ml of BBMV. In contrast, BpMV did not significantly inhibit platelet TXA2 (TXB2) production. These results show that syncytiotrophoblast brush border and basal plasma membranes of the human placenta have markedly different properties with respect to platelet aggregation inhibiting activity.

Platelet-aggregation inhibiting activity of human placental chorioepithelial brush border membrane vesicles and basal plasma membrane vesicles

Summary This laboratory investigated the platelet-aggregation inhibiting activity of human placental brush border membrane vesicles (BBMV) and basal plasma membrane vesicles (BpMV), and obtained the following results. o 1) A strong platelet-aggregation inhibiting activity exists in placental BBMW. In a 20 μg/ml protein concentration, the BBMV completely inhibited the secondary platelet aggregation induced by ADP. In a 40 μg/ml protein concentration, the BBMV completely inhibited the platelet aggregation induced by arachidonic acid and collagen, and in a 200 μg/ml protein concentration, the BBMV completely inhibited the platelet aggregation induced by ristocetin. However, placental BpMV did not show prominent platelet-aggregation inhibiting activity on platelet aggregation induced by ADP, arachidonic acid, collagen, or ristocetin. 2) A strong ADP degrading activity (ADPase activity) in the placental BBMV was found. ADP-degrading activity of the BBMV was 10.5±0.5 μmol/mg protein/minute and ADP-degrading activity of BpMV was 0.6±0.1 μmol/mg protein/minute. 3) The placental BBMV inhibited platelet thromboxane A 2 (TXA 2 ) production. In a 40 μg/ml protein concentration of placental BBMV, a platelet TXA 2 (TXB 2 ) production was almost completely inhibited. BpMV did not show prominent inhibitory activity on platelet TXA 2 (TXB 2 ) production. These results indicate that brush border membrane and basal plasma membrane have a different function in the respect of platelet-aggregation inhibiting activity, and that the brush border membrane may play an important role inhibiting platelet aggregation.